An intensive chemotherapy regimen (EVDAC), including high-dose epirubicin, vincristine, and dexamethasone followed by cyclophosphamide and high-dose cytarabine, was administered to 54 untreated adults with intermediate or high-grade non-Hodgkin's lymphomas (NHL). The median age was 59, 61 % were Ann Arbor Stage IV, 57%
therapy. Nearly all patients developed severe neutropenia. Febrile episodes requiring hospitalization during neutropenia occurred after 56% of courses of epirubicin, vincristine, and dexamethasone and after 9% of courses of cyclophosphamide and cytarabine; 80% of patients were hospitalized at least once. Platelet count nadirs of less than N RECENT YEARS there has been considerable interest I in designing chemotherapy regimens that may improve the cure rate in intermediate and high-grade non-Hodgkin's lymphomas (NHL). This has been accomplished by recognizing the importance of dose-intensity of each individual chemotherapeutic agent and/or by introducing multiple effective drugs (preferably without cross-resistance or overlapping toxicities) into therapy early in the course ofdisease. Many contemporary reports describe therapeutic success with regimens that use multiple Individual drugs generally are used in moderate doses, although toxicity caused by cumulative effects can be considerable. Exposure to many different agents enhances the possibility for idiosyncratic or rare side effects, as well as adverse drug interactions or additive toxicity. In addition, drugs may be added to regimens in dose schedules that have not been proven below normal levels), none have developed clinically evident congestive heart failure. Clinically significant mucositis occurred after only 8% of courses of high-dose epirubicin. Three deaths from infections and one from hyperkalemia with cardiac arrest occurred during therapy. These results confirm that high remission and sustained, failure-free survival rates can be achieved in patients with aggressive NHL, using high-dose anthracycline-containing chemotherapy regimens. Epirubicin appears to have an advantage over doxorubicin at high doses because of decreased toxicity at a therapeutically equivalent dose. These phase II study results need to be validated in a randomized phase 111 trial, and growth factors should be used to attempt to reduce the neutropenia-associated complications.
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effective when the drugs have been used alone. Less work has been performed in determining the value of smaller numbers of effective agents used at one time as primary therapy, with key drugs such as anthracyclines or cyclophosphamide being administered at maximal tolerated In 1985, our group reported the results of a study of highdose doxorubicin (Adriamycin) combination chemotherapy. for intermediate and high-grade lymphomas. 6 In that study patients received a regimen designated AVPAC, which consisted of 3 courses of doxorubicin at 120 mg/m2 with vincristine and prednisone, followed by 3 courses of cyclophosphamide (800 mg/m2 on day 1) and bolus cytarabine ( 3 g/m2 on days 1 and 8). Complete response (CR) or probable complete response (PCR) occurred in 85% of the patients studied. Sustained disease-free survival at a median of 33 months from completion of therapy was 64% for all patients started on treatment, excluding those with T-cell lymphoblastic lymphomas. Because nearly all of the patients had CR or PCR after the high-dose doxorubicin phase of therapy, we questioned whether the second phase of therapy was contributing to the outcome. Therefore, we conducted a follow-up phase I1 study using four courses, at 3-week intervals, of a regimen that we designated AVAD,' which consisted of 4 courses of high-dose doxorubicin ( 120 mg/m2) with vincristine, dexamethasone, and a single bolus per cycle of high-dose cytarabine (3 g/m2), the latter of which was included primarily for elimination of occult central nervous system (CNS) lymph~ma.'~ That study' showed response rates similar to those from our previous study: but a higher relapse rate, resulting in 51% of all patients who started on therapy remaining alive and free of lymphoma after a median of 58+ months. These results still appeared to be substantially better than the approximately 27% to 32% of all patients started on treatment with the widely used cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), who are sustained failure-free doses.6.7. survivors. 13-17,24-32 However, there was a high incidence of poorly tolerated side effects, particularly mucositis, neutropenia, and thrombocytopenia, associated with the use of doxorubicin at a dose of 120 mg/m236,7218 and the relapse rate observed with the AVAD regimen' raised additional concerns. Because high-dose 4'-epirubicin, a doxorubicin analog, was reported to be associated with a lower incidence of thrombocytopenia and mucositis than was purportedly equivalently high-dose d o x~r u b i c i n ,~~~* '~,~~ we designed a regimen similar to our original high-dose (1 20 mg/m2) doxorubicin-containing treatment but with what is thought to be approximately a therapeutically equivalent dose ( 1 80 mg/m2) of e p i r u b i~i n ,~"~~ approximately twice the previously used standard dose of approximately 90 mg/m2 of epirubicin. We now report the results of treatment of intermediate and high-grade NHL with an intensive chemotherapy regimen called EVDAC, in which the primary active component was high-dose epirubicin.
MATERIALS AND METHODS
This study was approved by the Institutional Review Boards of the University of Alabama at Birmingham (Birmingham, AL) and the Maine Center for Cancer Medicine (Portland, ME), and informed consent was obtained from all patients entering the study. Between November 1986 and February 1989, 54 eligible patients with intermediate or high-grade NHL were entered into the EV-DAC study. Eligibility was limited to patients over 18 years old (no upper age limit) with appropriate histologies (follicular large-cell lymphoma, diffuse small cleaved-cell lymphoma, diffuse mixed lymphoma, diffuse and follicular large-cell or mixed lymphoma, diffuse immunoblastic or nonimmunoblastic large-cell lymphoma, and diffuse small noncleaved cell/undifferentiated Burkitt's or nonBurkitt's lymphoma), who had disease in at least two sites and who had received no prior chemotherapy. Patients with lymphoblastic lymphoma and patients known to be infected with human immunodeficiency virus were not eligible. Total bilirubin no greater than I .3 mg/dL, normal cardiac ejection fraction by resting radionuclide ventriculography, and no evidence of central nervous system involvement were also required. Pretreatment evaluation included a complete history and physical examination, complete blood counts, blood chemistries, chest X-ray, chest computed tomography (CT) scan (optional), abdominal and pelvic CT scans, unilateral or bilateral bone marrow biopsy, radionuclide ventriculography, lumbar puncture with cytologic analysis, and other diagnostic studies indicated by each patient's clinical ~tatus.6~ Gallium scanning was not performed routinely before or after therapy.
Therapy consisted of an initial 3 cycles of epirubicin 180 mg/mz, vincristine 2 mg total dose, and dexamethasone 20 mg/m2 intravenously (IV), all administered on day I , and dexamethasone 20 mg/ m2 orally on days 2 through 5. Three weeks after the third of these courses was administered, patients received their first of 3 cycles of cyclophosphamide 800 mg/m2 IV on day 1 and cytarabine 3,000 mg/m2 IV infusion over 2 hours on days 1 and 8. All 6 courses of therapy were administered at 2 I-day intervals, if blood counts and patient condition permitted. If the absolute neutrophil count was less than l,500/pL or if the platelet count was less than lOO,OOO/pL on day 22 (day 1 ofthe next scheduled course oftherapy), treatment was postponed for 1 week at a time until the absolute neutrophil count was 2 1,5OO/pL and the platelet count was 2 lOO,OOO/pL. Chemotherapy drug doses were never reduced. Patients had repeat examinations before each course of therapy. Scans or radiographs of areas of initial involvement were repeated after the first 3 courses of therapy, 3 to 5 weeks after the end of treatment, and whenever possible at 3, 6, 12, 18, 24, and 36 months after completion of therapy.
Statistical analysis. CR was defined as the disappearance of all clinical evidence of disease, including normalization of radiographic abnormalities that had been present before therapy. To qualify as a CR there could be no evidence of relapse for at least 1 month. A number of patients with lymphomas achieve what previously has been classified in many instances as a partial response. However, many of these so-called partial responders have rapid disappearance of palpable masses and rapid, >50% decreases in the size of radiographically detected masses, which then remain tpe same size over extended periods of time (at least 2 to 4 months). Generally, these are patients who present initially with bulky retroperitoneal, intraabdominal, mediastinal, and/or extranodal disease. We have designated this group of patients as having PCR, for lack of more accurate terminology. Because the prognosis of PCR patients is no different than that for those patients who attained a classical CR (Dabich et a1, 6 Zuckerman et al, 7 Coiffer et al,8 Sprbone et al," and the present study), the CR and PCR patients have been grouped together for most analyses in this report. Survival curves were generated using the Kaplan-Meier method.38 Sustained failure-free survival is defined in this report as CR or PCR and survival as of July 1993, without any recurrence of lymphoma since beginning therapy. Death from any cause is considered to be a failure for the purposes of this analysis. At the time of this analysis in July 1993, the median follow-up from the beginning of therapy was 66+ months (range, 53+ to 80+ months). For the generation of data on failure-free survival, death from any cause, initial treatment failure (even if salvaged and possibly cured with subsequent chemotherapy), and relapse after achieving an initial remission are all considered to be failures at the time of occurrence of the event that defined the failure. x2 tests were used to analyze relations between prognostic factors and response (CR and PCR) rate. Log rank and Cox proportional hazards models were used to analyze the correlations of single and multiple potential prognostic factors with sustained failure-free ~urvival.~'
RESULTS
Patient characteristics. The key patient characteristics are depicted in Table 1 . The median age of patients entered on this study was 59 years, and 17% were over 70 years old. A total of 61 percent of patients had stage IV disease, and 24% had stage 111 disease (by the Ann Arbor Hodgkin's Disease staging criteria). Of the 8 patients (1 5%) who had stage I1 disease, 5 had masses 2 7 cm in diameter, 2 had "B' symptoms, and 4 had lactate dehydrogenase (LDH) levels greater than 250 U/L. Although the Ann Arbor staging system apparently may have only moderate use in NHL, we have used it to allow comparison with other studies in the literature that report this information. A total of 57% of patients had "B' symptoms (fever, night sweats, and/or > 10% weight loss); 50% of patients had LDH levels greater than 250 U/L; 48% of patients had bulky disease, which was characterized by the presence of at least one mass that was 27 cm in diameter; and 33% had at least one mass of 2 Two important caveats in this multiple risk factor analysis need to be addressed with respect to the current study. First, we substituted a Karnofsky score of ~7 0 % for an ECOG score of 22, and the Karnofsky performance status for many of the patients in this study was not reported prospectively, but was estimated retrospectively from reviewing the charts. The authors believe that the reported Karnofsky scores have underestimated severity of illness in many cases, but no attempt has been made to correct these scores. Second, the investigators-were not required to list all sites of disease involvement; they were required only to document at least one extranodal site of involvement, which inevitably leads to an under reporting of the number of patients with more than 1 extranodal site. Thus, the results that we used for this analysis may underestimate the true severity of disease in this patient population.
Response rates, survival rates, and assessment of predictive value ofprognostic factors. Results are reported for all eligible patients entered on protocol. A summary of the initial response data is presented in Table 2 . The overall CR plus PCR rate for all entered patients was 76% (41 of 54 patients). Two patients died before a determination regarding response to therapy could be made, 1 of sepsis during neutropenia and 1 of hyperkalemia and cardiac arrest. Of the 11 patients judged to have partial response, stable disease, or progression of lymphoma while receiving EVDAC, 10 died, and 1 is currently disease-free 69+ months after diagnosis, after salvage chemotherapy.
Approximately 59% to 77% ofall patients with such previously described adverse prognostic factors as age over 60 years, extranodal (stage IV) involvement, "B" symptoms, elevated pretreatment serum LDH level, and masses over 7 (or 10) cm in diameter achieved a CR or PCR ( Table 2) . Of these prognostic factors, only presence of at least one "B" symptom or serum LDH levels above 250 U/L had a statistically significant negative relationship with initial response rate.
Most importantly, as of July 1993, 32 of the original 54 patients started on the EVDAC protocol (59%) remain alive, well, and free of any evidence of lymphoma 53+ to 80+ months from the initiation and 49+ to 76+ months from completion of their EVDAC chemotherapy (median All 54 patients who were started on therapy, including 2 patients who died 1 and 1 '/2 weeks after initiation of therapy and are considered as nonresponders, are included in these data. CR and PCR patient data were virtually identical and were combined for these analyses. Percentages are shown in parentheses.
Abbreviations: NS, not significant (P > .05); x2 analysis.
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66+ months from the beginning and 62+ months from the end of therapy). Among the 30 diffuse large-cell lymphoma (DLCL) patients started on therapy, 18 (60%) are still alive and in first remissions of their lymphomas. Of patients with other histologies, 14 of 24 (58%) are alive and in first remission of their lymphomas. Only 3 of the 23 patients with DLCL who achieved CR or PCR have relapsed (7, 10 , and 47 months from the end of therapy). Interestingly, among the 18 patients with diffuse mixed lymphoma (DML), diffuse and follicular large cell lymphoma (D/FLCL), diffuse and follicular mixed lymphoma (D/FML), or diffuse small cleaved-cell lymphoma (DSCCL) who achieved CR or PCR, only 2 have relapsed (1 9 and 46 months from the end of therapy). Thus, it appears likely that a very high portion of patients with intermediate grade NHL other than DLCL also may be curable using this type of treatment. We were unable to detect any clinical or laboratory feature that predicted likelihood of relapse, but this most likely was a reflection of the low incidence of relapses (5 of 41). A KaplanMeier plot of overall survival of all patients entered into the study is depicted in The correlations of several of the widely accepted prognostic variables with sustained failure-free survival in our patient population are shown in Table 3 . Although the data in this table report the actual numbers of current failure-free survivors as of July 1993, with the follow-up as described above and as shown graphically in Fig 3, the reported significance of each of the prognostic factors shown in this table was determined by log rank analysis of potential prognostic factors versus duration of failure-free survival. There was no difference in sustained failure-free survival between patients with DLCL (immunoblastic and nonimmunoblastic) and those with other intermediate grade lymphomas. Considered as single prognostic factors, age, sex, stage, and presence or absence of extranodal lymphoma involvement or bulky masses (27 cm or 210 cm) before the initiation of chemotherapy, were not predictive of sustained failure-free survival and (presumably) cure. Of all these potential prognostic features that we evaluated by log rank analysis, the only individual factors that were associated with a significantly reduced chance of sustained failure-free survival were "B' symptoms and high pretreatment serum LDH levels, the same factors associated with a reduced chance of achieving apparent CR or PCR. Of course, it is possible that some of the single factors that did not distinguish poorerfrom better-prognosis patients in this study could prove to be of prognostic value if a substantially larger number of patients were to be treated with this regimen. A Cox proportional hazards model using three covariates, older age, "B" symptoms, and high LDH, showed a significant adverse correlation (P = .022) with failure-free survival. In this model, when we adjusted for the confounding covariates, "B" symptoms and high LDH, older age (260) also appeared to be a significant adverse prognostic factor. Cox models using additional covariates showed no significant correlation with failure-free survival. Time from End of Therapy (Months) marized in Table 4 . Neutropenia was the only clinically significant toxicity that occurred, Neutrophil counts predictably fell to fewer than 500 cells/pL in the majority of patients within 8 to 10 days after treatment. Peripheral blood neutrophil count recovery generally began at day 14 to 16 and was 2 1 ,500lpL by day 17 to 2 1 in nearly all cases, and symptoms resolved when blood count recovery occurred. A total of 56% of the delivered courses of high-dose epirubicin, vincristine, and dexamethasone were accompanied by febrile episodes that occurred during neutropenia and, hence, required hospitalization, whereas only 9% of courses of cyclophosphamide and cytarabine were associated with neutropenic, febrile episodes. A total of 80% of patients had at The duration of relapse-free survival (from the end of therapy) for all 41 patients who achieved a CR or PCR to EVDAC chemotherapy is shown. All patients who have relapsed or who have died from any cause after first achieving a CR or PCR are considered not to be relapse-free survivors. Although the survival curve appears to begin at 95% instead of 100%. this is a result of 2 patients who achieved CR, but subsequently died before the scheduled completion of chemotherapy. Thus, they were considered to be deaths at 0 months after completion of therapy.
Time from Beginning of Therapy (Months)
least one hospitalization. Of the 4 patients (7%) who died during therapy, 3 died because of sepsis during neutropenia, and one died from hyperkalemia and cardiac arrest. Platelet counts less than 50,OOO/pL occurred after only 5% of highdose epirubicin-containing treatment courses; a count of less than 20,00O/pL (19,000) occurred after only 1 of 146 evaluable courses, and there were no episodes of serious bleeding during the study. Although 13% of courses of cyclophosphamide and cytarabine were followed by platelet counts less than 50,OOO/pL, no patients had severe thrombocytopenia (platelets <20,OOO/pL) after receiving the cyclophosphamide and cytarabine portion of the treatment regimen. Clinically significant oropharyngeal mucositis All patients still alive and in first remission of lymphoma 49+ to 76+ (median 62+) months after completion and 53+ to 80+ (median 66+) months after initiation of therapy. Percentages are shown in parentheses.
Abbreviations: NS, not significant (P > .05); log rank analysis.
(grade 3 or 4) was observed after only 8% of courses of highdose epirubicin and did not occur after cyclophosphamide and cytarabine. Peripheral neuropathy presumably related to vincristine was a minor problem in a small number of patients. Nausea and vomiting were controlled relatively easily with aggressive antiemetic therapy. No patient developed cerebellar or ocular toxicity related to cytarabine administration. Several patients received their first course of chemotherapy in the hospital immediately after their diagnostic evaluations, mainly for patient convenience. However, nearly all other treatment courses were delivered in an outpatient facility, with hospitalization being required only for complications of the lymphoma or the therapy. i As anticipated from the results of our prior high-dose ' doxorubicin studies6,' and phase I high-dose epirubicin studies," clinically evident cardiotoxicity did not occur in any of the patients in this study. No patients had acute arrhythmias temporally related to epirubicin infusions. The mean left ventricular ejection fraction in our patient population, as determined by radionuclide ventriculography, was 0.63 before EVDAC therapy and 0.56 after completion of therapy. A total of 8 patients had a greater than 0.12 decrease (or 20% below their baseline values) decline in ejection fraction, 5 to below normal levels, although none of them developed clinical signs or symptoms of congestive heart failure, with 4 or more years of follow-up in all cases.
Despite the toxicity described above for the EVDAC regimen and the age of our patients, 48 of the 54 patients completed all 3 of the planned courses of high-dose epirubicin, vincristine, and dexamethasone (with no dose reductions), and 41 of the 54 patients completed all 6 of the planned treatment courses. Of the 13 patients who did not complete the prescribed 6 courses of treatment, 4 died before treatment could be completed, and 8 had progressive disease or no objective improvement on therapy; 1 patient refused her final course of cyclophosphamide and cytarabine, but she remains a failure-free survivor 54-t months after stopping treatment. The mean duration of therapy among the 42 patients that completed all 6 treatments (calculated from the first treatment day to 3 weeks after the final treatment) was 134 days (range, 126 to 168 days), versus a planned duration of 126 days. A total of 3 of the 4 patients who had total delays of at least 2 1 days before completion of the epirubicin-containing treatments eventually died of lymphoma. The actual delivered dose intensity for all 154 courses of epirubicin administered to all 54 patients treated with EVDAC (also calculated from the first treatment day to 3 weeks after the final treatment, using the method of Hryniuk and Bush4') was 54.9 mg/m2/week, which was 9 I .5% ofthe planned dose intensity of 60 mg/m2/ week. Because no patient received a reduced dose of epirubicin at any time, the 8.5% reduction below the planned dose intensity was caused entirely by delays in administration of courses of therapy.
Epirubicin dose intensity.

DISCUSSION
The previous results using 3 cycles of high-dose doxorubicin induction therapy followed by a consolidation phase of For
cyclophosphamide and cytosine arabinoside (AVPAC) produced a high complete remission rate and extremely low relapse rate in patients with intermediate and high-grade (other than T-cell lymphoblastic) NHL.6 In that study, most patients responded rapidly during the induction phase, and the rapid responders ultimately did well, as has been reported elsewhere.42 Our current study results also are in general agreement with the previous observations that rapid response to initial therapy of DLCL is a good prognostic feature for sustained failure-free survival. The current regimen was designed to determine whether we could maintain or improve on the prior AVPAC regimen results with the substitution of epirubicin, in what is thought to be a therapeutically equivalent dose ( 180 mg/m2/dose), for doxorubicin, which had been administered at a dose of I20 mg/m2/ dose. Cyclophosphamide was administered in a "consolidation" phase, rather than during epirubicin administration, to prevent overlapping myelosuppression, which might have compromised the ability of patients to receive the desired dose intensity of epirubicin. Based on the significantly higher relapse rate that was observed when we studied a similar group of patients treated with AVAD (high-dose doxorubicin, but no cycl~phosphamide),~ in comparison with the results of treatment with AVPAC; we felt that the cyclophosphamide consolidation phase of treatment that was used in the original AVPAC study might well have been important for optimizing the chances of patients achieving sustained failure-free survival. Cytarabine was included for CNS "prophylaxis" based on the observation that a single dose of 3 g/m2 will provide therapeutic, cytotoxic levels in the cerebrospinal fluid for approximately 24 hours. 23 As was true of the patients treated in our previous highdose anthracycline studies6z7 our group of 54 patients with intermediate and high-grade lymphomas treated with the EVDAC regimen generally were as old or older (26 of 54 older than 60 years) and presented with as advanced or more advanced stage of disease (32 of 54 were stage IV) and as bulky or more bulky disease (26 of 54 with masses 2 7 cm in diameter, 18 of 54 patients with masses 2 10 cm, 27 of 54 with an LDH level >250 U/L, and 3 I of 54 with "B" symptoms) than those in other patient populations reported in studies of the use of aggressive "third generation" regimen~.'-'~ All the above have been reported to be poor prognostic variables in studies in which less intensive chemotherapeutic regimens were used.'3,'4,24,26,43-54 Analysis of the prognostic factors identified by The International NonHodgkin's Lymphoma Prognostic Factors Project4' (age, >60; stage 111 or IV; > 1 extranodal site of disease; ECOG performance status, 22; and LDH above the normal range), showed that our patient population is comparable with that of the overall population of patients with aggressive NHL, who have been treated with other chemotherapy regimens. Using their multiple prognostic factor risk groups, our population included 35% low risk, 19% low-intermediate risk, 28% high-intermediate risk, and 19% high risk patients, as compared with their group of 3,273 patients that included 35% low risk, 27% low-intermediate risk, 22% high-intermediate risk, and 16% high risk patient^.^' Recent reviews have suggested other prognostic factors, such as @,-microglobulin, hepatic abnormalities, hemoglobin concentration, cytogenetic abnormalities, and proliferative rate that also may be worthy of consideration in designing and analyzing future studies of therapy for NHL.55-57 Although the predictive value of many of the potentially important individual prognostic factors in this study population has been reported above, the number of patients in the current study is insufficient to analyze the actual prognostic value of subsets of multiple factors in individual patients in this relatively small clinical trial.
The EVDAC regimen was very effective in inducing CR and PCR of disease in this patient population. The overall CR/PCR rate is 7676, and much more importantly, the proportion of patients that remain alive and in first remission is 59% at a median of 63+ (range, 49+ to 76+) months from the time of completion of EVDAC therapy (actuarial failure-free/event-free survival at 6 to 7 years is 50%). These results are comparable with those of multiple phase I1 studies of third generation chemotherapy regimens for treating intermediate and high-grade NHL,'-I7 although it should be noted that several two-armed studies of CHOP versus one of the third generation and the recent analysis of the results of the large Southwest Oncology Group randomized phase 111 trial comparing CHOP, m-BACOD, MA-COP-B, and ProMACE-CytaBOM show no significant differences in outcome between CHOP and any of the three third generation treatment regimens.6' The results of the present study appear to confirm the findings obtained in our prior similar phase I1 studies of high-dose anthracyclinebased therapy of these lymphoma^,^,' which suggest that there may be a failure-free survival advantage of high-dose anthracycline-based regimens over CHOP.
Although the responses and sustained failure-free survival rates are nearly identical with the AVPAC and EV-DAC regimens, high-dose epirubicin appears to have a substantial advantage over comparably high-dose doxorubicin in terms of the toxicity profiles of these two anthracyclines. In particular, the high-dose doxorubicin is associated with an extremely high (>80%) incidence of severe (grade 3 or 4) oropharyngeal mucositis,6s7 whereas clinically significant mucositis occurs after fewer than 10% of courses of highdose (1 80 mg/m2) epirubicin. Furthermore, potentially clinically significant thrombocytopenia is extremely rare after this dose of epirubicin, but occurs after at least 20% of courses of high-dose (120 mg/m2) dox~rubicin.~.~ Preclinical and initial phase I and I1 studies in humans suggest that the dose equivalency ratio for epirubicin to doxorubicin is approximately 1.5: 1 ,33-36 which makes the actual delivered dose intensity of epirubicin in the current study (54.9 mg/m2/week) equivalent to 36.6 mg/m2/week of doxorubicin. The doxorubicin dose intensity for our most recent prior high-dose doxorubicin regimen' was 34.4 mg/m2/week. In comparison, the doxorubicin dose intensity in CHOP regimens administered every 3 to 4 weeks at full doses of 50 to 60 mg/m2/dose is 12.5 to 20 mg/m2/week.
The current study, with results similar to those of two prior single-institution phase I1 s t~d i e s~,~ of high-dose doxorubicin-containing chemotherapy regimens, shows sustained failure-free actuarial survival rates of 60% at 3 to 4 years and 50% at 4 to 7 years, which is substantially in excess of the 27% to 32% long-term failure-free survival rates reported for the less intensive, CHOP and related regiThere are several lessons to be gleaned from the results of this and our prior high-dose anthracycline clinical trials. (1) High-dose anthracycline-containing regimens are very effective in inducing CR and sustained failure-free survival in patients with aggressive NHL, even in patients with several features that have been reported in the past to indicate a poor prognosis. (2) Intensive chemotherapeutic regimens containing very high doses of anthracyclines, without provisions for dose reductions, can be tolerated sufficiently well, even by older patients, so that the vast majority of patients can complete the planned course of therapy. (3) Although nearly all patients who achieve what is defined ultimately as a CR or PCR do so by the time of completion of the 3 courses of epirubicin or doxorubicin, the cyclophosphamide administration in a consolidation phase of therapy may be important in achieving a high cure rate. (4) Sustained failure-free survival can be achieved for a substantial majority of patients not only with DLCL but also with other intermediate-grade (or low-intermediate grade) lymphomas, using the EVDAC and AVPAC regimens. (5) Patients with residual masses less than 50% of the maximal two-dimensional pretreatment size, which remain stable in size for at least 2 to 4 months after the end of any of our intensive, high-dose anthracycline-based chemotherapy regimens (which we have defined as PCR) have a prognosis that is identical to that of patients who have no evidence of residual masses (CR); thus, the residual masses that meet these criteria are likely not to contain viable lymphoma cells and can be followed expectantly, and these patients probably should be considered in the future to be true complete responders (Dabich et Zuckerman et al,7 Coiffer et al,' Surbone et and the present study). We believe that it is a contradiction in terms to consider these patients as having only a partial response, because a substantial majority of patients who achieve PCR (78% in the present study, after a minimum follow-up of 4 years) are survivors in sustained first remissions, who are apparently cured of their lymphomas ( Zuckerman et and the present study) using only high-dose doxorubicin or epirubicin, vincristine, dexamethasone, and high-dose mens. 13-17.2432 cytarabine (the latter given only once or twice per course for 3 to 4 courses, primarily for CNS coverage), plus or minus cyclophosphamide. To maximize the dose of anthracycline that could be tolerated by the patients, we believe that it is critical to optimize the dosing schedule so that no other myelosuppressive agent is used concurrently during the courses of treatment in which the high-dose anthracycline is administered. This approach to optimizing dosage of key drugs has resulted in remission and sustained failure-free survival rates that appear to be comparable with or superior to those reported for other more complex regimens involving greater numbers of drugs. Another point of great importance is that, to assess the true efficacy of this intense chemotherapy, it is necessary to treat patients at the full doses suggested and not to reduce the dose of the anthracyclines on any course of therapy because of presumed impaired bone marrow reserves, age, or myelosuppression after a prior course of therapy. Certainly, the ability to assess the true potential efficacy of other intensive regimens in treating aggressive NHL has been impaired in studies in which substantial numbers of patients received significant dose reductions.
The availability of granulocyte-macrophage colony-stimulating factor, granulocyte colony stimulating factor, and other currently investigational therapies for attempting to ameliorate or shorten the duration of myelosuppression makes it possible to design new regimens similar to EVDAC or AVPAC, which are likely to reduce substantially the incidence (56% of high-dose epirubicin-containing courses in this study) of febrile neutropenic episodes requiring parenteral antibiotics and hospitalization. If concerns over the possible enhancement of myelosuppressive effects of cytotoxic chemotherapeutic agents by hemopoietic growth factors (which induce hemopoietic progenitor cells into active cell cycling) administered simultaneously with the chemotherapeutic agents are proven to be a significant clinical problem, the EVDAC and AVPAC regimens, with myelosuppressive drug administration only on day 1 of each cycle, are optimally adaptable to growth factor administration. In addition, the use of growth factors along with the EVDAC or AVPAC chemotherapy program would permit studies of the value of further dose intensification and shortened total time of treatment, particularly by allowing some patients to be treated at 2-week instead of 3-week intervals.
The results of this and our previous phase I1 high-dose anthracycline-based studies in patients with intermediate and high-grade NHL suggest that randomized trials designed to assess the potential beneficial effects of increased anthracycline dose intensity in the treatment of such patients are warranted. 
